The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study

被引:6
|
作者
Talks, S. James [1 ]
Daien, Vincent [2 ]
Mitchell, Paul [3 ]
Aslam, Tariq [4 ,5 ]
Barratt, Jane [6 ]
Biberger, Anna [7 ]
Lamoureux, Ecosse L. [8 ,9 ]
Hirst, Ceri [10 ]
Sylvanowicz, Michelle [10 ]
Finger, Robert P. [11 ]
机构
[1] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle Eye Ctr, Newcastle Upon Tyne, England
[2] Univ Hosp Montpellier, Dept Ophthalmol, Montpellier, France
[3] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia
[4] Manchester Royal Eye Hosp, Manchester, England
[5] Univ Manchester, Manchester, England
[6] Int Federat Ageing, Toronto, ON, Canada
[7] Cerner Enviza, Munich, Germany
[8] Singapore Eye Res Inst, Singapore, Singapore
[9] Duke NUS Med Sch, Singapore, Singapore
[10] Bayer Consumer Care AG, Basel, Switzerland
[11] Univ Bonn, Dept Ophthalmol, Bonn, Germany
关键词
nAMD; Anti-VEGF; Patient care; Communication; Adherence; Persistence; Emotion; ANTI-VEGF TREATMENT; GROWTH-FACTOR THERAPY; DEPRESSION; EXPERIENCE; OUTCOMES; ANXIETY;
D O I
10.1007/s40123-022-00631-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction: Visual impairment resulting from diseases such as neovascular age-related macular degeneration (nAMD) may cause behavioural, environmental, psychological, and logistical challenges that could act as barriers to effective uptake and sustainability of treatment with anti-vascular endothelial growth factor agents (anti-VEGFs). Understanding emotions and experiences of patients with nAMD may help inform the determinants of adherence, and could contribute to improvements in ophthalmic outcomes and quality of life. Methods: Seventeen patients with nAMD receiving anti-VEGF injections were enrolled from three clinics: one each in France (n = 5), Germany (n = 6), and the UK (n = 6). Patients' health information and treatment characteristics were collected. Individual phone interviews were conducted by experienced health care interviewers. Transcripts were analysed thematically. Results: Patients (53% female) had a mean age of 77 years. Bilateral anti-VEGF injections were received by 24% (n = 4); and most (76%, n = 13) were adherent to their treatment. Patient emotions at diagnosis ranged from happiness at learning about the treatment for nAMD to being terrified of receiving an injection in the eye. Most patients mentioned feeling anxious and fearful before their first injection despite receiving reassurance. After the first injection, these feelings and apprehension abated for many, but not all. With the goal of maintaining the best possible vision, few (24%, n = 4) patients reported more than one missed appointment, and most had never considered stopping treatment. No patient reported additional assistance beyond family support; however, many had difficulties with recreational and domestic activities and had developed coping strategies. Conclusion: This study provides insights on patients' emotions related to their experience of nAMD and its management, highlighting the varying experiences between individuals. It shows the importance of the patient's voice when considering patient care and management, and how the nature and timing of interventions can improve the experience of living with and managing nAMD.
引用
收藏
页码:561 / 575
页数:15
相关论文
共 50 条
  • [21] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [22] Ranibizumab for neovascular age-related macular degeneration
    Hernandez-Pastor, Luis Javier
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (19) : 1805 - 1814
  • [23] Radiotherapy for neovascular age-related macular degeneration
    Evans, Jennifer R.
    Igwe, Chinedu
    Jackson, Timothy L.
    Chong, Victor
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (08):
  • [24] The burden of neovascular age-related macular degeneration: a patient's perspective
    Spooner, Kimberly L.
    Mhlanga, Cleopatra T.
    Hong, Thomas H.
    Broadhead, Geoffrey K.
    Chang, Andrew A.
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 2483 - 2491
  • [25] An epidemiological study of neovascular age-related macular degeneration in Germany
    Krause, Lothar
    Yousif, Tarik
    Pohl, Karin
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (10) : 1391 - 1397
  • [26] Treatment of age-related neovascular macular degeneration: the patient's perspective
    Mueller, S.
    Ehlken, C.
    Bauer-Steinhusen, U.
    Lechtenfeld, W.
    Hasanbasic, Z.
    Agostini, H.
    Wilke, T.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (11) : 2237 - 2246
  • [27] Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
    Van Cleemput, Liesbeth
    Peeters, Freya
    Jacob, Julie
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1077 - 1085
  • [28] Treatment of age-related neovascular macular degeneration: the patient’s perspective
    S. Müller
    C. Ehlken
    U. Bauer-Steinhusen
    W. Lechtenfeld
    Z. Hasanbasic
    H. Agostini
    T. Wilke
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 2237 - 2246
  • [29] Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration
    Jelin, Elma
    Wisloff, Torbjorn
    Moe, Morten C.
    Heiberg, Turid
    ACTA OPHTHALMOLOGICA, 2018, 96 (08) : 804 - 811
  • [30] Peripheral Autofluorescence and Clinical Findings in Neovascular and Non-neovascular Age-related Macular Degeneration
    Tan, Colin S.
    Heussen, Florian
    Sadda, SriniVas R.
    OPHTHALMOLOGY, 2013, 120 (06) : 1271 - 1277